<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328118</url>
  </required_header>
  <id_info>
    <org_study_id>PDR-RAN-LSY</org_study_id>
    <nct_id>NCT02328118</nct_id>
  </id_info>
  <brief_title>25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China</brief_title>
  <acronym>RaTAPDR</acronym>
  <official_title>25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JUNYAN ZHANG</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First People's Hospital of Xuzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First People's Hospital of Xuzhou</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic
      patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth
      factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic
      patients. The operation indication includes non-absorbed vitreous haemorrhage, dense bleeding
      in front of the macular, proliferative vitreoretinopathy traction macular, tractional retinal
      detachment combined break, severe progressive fiber vascular proliferation and vitreous
      haemorrhage combined with early iris neovascularization.

      Due to VEGF levels rise in vitreous cavity of PDR patients, some inflammatory cytokines
      involved in, make easy bleeding during surgery and heavier inflammatory reaction
      postoperation,thus affecting the curative effect of the operation.

      Ranibizumab as angiogenesis inhibitors, has widely applied in the treatment of age-related
      macular degeneration, won the recognition of ophthalmologists.

      Some scholars try to expand the application in diabetic macular edema, also obtained the good
      curative effect.Some scholars also applied the angiogenesis inhibitors to the diabetes
      retinopathy before surgery in the hope to reduce the occurrence of intraoperative
      bleeding.Compared with bevacizumab, the short half-life of lucentis, and thus reduce the
      inhibition of VEGF system risk.

      In this project, the investigators will inject lucentis into vitreous cavity before surgery
      of PDR, and observe the effect and complications of the operation, compared with
      triamcinolone acetonide group(the control group); At the same time the cytokines level of
      VEGF, pigment epithelium-derived factor (PEDF), epidermal growth factor (EGF), Transforming
      Growth Factor-beta (TGF-beta), interleukin 6 (IL - 6) and interleukin 8 (IL - 8) will be
      detected before and after pretreatment with lucentis or triamcinolone acetonide, and the
      cytokines concentration change will be compared between two groups, the mechanism of PDR will
      be further clarified and theoretical basis for looking for treatment strategies will be laid.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite outcome including amotio retinae,vitreous hemorrhage within 12 months after vitrectomy</measure>
    <time_frame>12 months after the last subject accepts vitrectomy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of Best-corrected visual acuity</measure>
    <time_frame>the change of best-corrected visual acuity at month 12 after vitrectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of inflammatory factors in vitreous body</measure>
    <time_frame>7 days after injection</time_frame>
    <description>Compare the change of inflammatory factors in vitreous chamber between two groups. These inflammatory factors including VEGF/PEDF,EGF/TGF-beta, IL-6 and IL-8. This is only focus before vitrectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Acetonide 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.</description>
    <arm_group_label>Ranibizumab 0.5 mg</arm_group_label>
    <other_name>Lucentis</other_name>
    <other_name>rhuFab V2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.</description>
    <arm_group_label>Ranibizumab 0.5 mg</arm_group_label>
    <arm_group_label>Triamcinolone Acetonide 4mg</arm_group_label>
    <other_name>Vitreal S</other_name>
    <other_name>Cinonide</other_name>
    <other_name>Tricort 40</other_name>
    <other_name>Kenalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II diabetes mellitus with Diabetic Retinopathy

          -  Vitreous hemorrhage/Proliferation of retinal/Tractional detachment of retina

          -  Fasting blood-glucose no more than 8mmol/ml

        Exclusion Criteria:

          -  Subjects who have operation on vitreous before

          -  Accompany with other ophthalmology diseases except cataract

          -  History of vitrectomy surgery in the study eye

          -  Previous subfoveal focal laser photocoagulation in the study eye

          -  Previous participation in a clinical trial (for either eye)

          -  Previous subfoveal focal laser photocoagulation in the study eye

          -  Other diseases cannot afford Vitrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SUYAN LI, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmology Department of the 1st People Hospital of Xuzhou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SUYAN LI, Doctor</last_name>
    <phone>+86-13852101175</phone>
    <email>lisuyan1226@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JUNYAN ZHANG, bachelor</last_name>
    <phone>+86-13701739364</phone>
    <email>richard.zhang@both-win.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First People Hospital of Xuzhou</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suyan Li, Doctor</last_name>
      <phone>+86-13852101775</phone>
      <email>lisuyan1226@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Junyan Zhang, Bachelor</last_name>
      <phone>+86-13701739364</phone>
      <email>richard.zhang@both-win.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Guthoff R, Riederle H, Meinhardt B, Goebel W. Subclinical choroidal detachment at sclerotomy sites after 23-gauge vitrectomy: analysis by anterior segment optical coherence tomography. Ophthalmologica. 2010;224(5):301-7. doi: 10.1159/000298750. Epub 2010 Mar 23.</citation>
    <PMID>20332654</PMID>
  </reference>
  <reference>
    <citation>Dehghan MH, Salehipour M, Naghib J, Babaeian M, Karimi S, Yaseri M. Pars plana vitrectomy with internal limiting membrane peeling for refractory diffuse diabetic macular edema. J Ophthalmic Vis Res. 2010 Jul;5(3):162-7.</citation>
    <PMID>22737351</PMID>
  </reference>
  <reference>
    <citation>Cho M, D'Amico DJ. Transconjunctival 25-gauge pars plana vitrectomy and internal limiting membrane peeling for chronic macular edema. Clin Ophthalmol. 2012;6:981-9. doi: 10.2147/OPTH.S33391. Epub 2012 Jul 6.</citation>
    <PMID>22848140</PMID>
  </reference>
  <reference>
    <citation>Song SJ, Sohn JH, Park KH. Evaluation of the efficacy of vitrectomy for persistent diabetic macular edema and associated factors predicting outcome. Korean J Ophthalmol. 2007 Sep;21(3):146-50.</citation>
    <PMID>17804919</PMID>
  </reference>
  <reference>
    <citation>Gupta V, Arevalo JF. Surgical management of diabetic retinopathy. Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):283-92. doi: 10.4103/0974-9233.120003. Review.</citation>
    <PMID>24339677</PMID>
  </reference>
  <reference>
    <citation>Hanan N AI Shamsi, Jluwi S Masaud, Nicola G Ghazi.Diabetic macularedema :New promising therapies.World J Diabetic.2013;15:4(6).:324-4338</citation>
  </reference>
  <reference>
    <citation>Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes. 2011 Jun 15;2(6):98-104. doi: 10.4239/wjd.v2.i6.98.</citation>
    <PMID>21860693</PMID>
  </reference>
  <reference>
    <citation>Bainbridge J. Refractory diabetic macular edema. J Ophthalmic Vis Res. 2010 Jul;5(3):143-4.</citation>
    <PMID>22737347</PMID>
  </reference>
  <reference>
    <citation>Jahn CE, TÃ¶pfner von Schutz K, Richter J, Boller J, Kron M. Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy. Ophthalmologica. 2004 Nov-Dec;218(6):378-84.</citation>
    <PMID>15564755</PMID>
  </reference>
  <reference>
    <citation>Robaszkiewicz J, Chmielewska K, Wierzbowska J, Figurska M, Frontczak-Baniewicz M, Stankiewicz A. [Combined surgical and pharmacological treatment of diabetic maculopathy]. Klin Oczna. 2010;112(1-3):19-23. Review. Polish.</citation>
    <PMID>20572497</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2014</study_first_submitted>
  <study_first_submitted_qc>December 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First People's Hospital of Xuzhou</investigator_affiliation>
    <investigator_full_name>JUNYAN ZHANG</investigator_full_name>
    <investigator_title>Senior Consultant and Statistician</investigator_title>
  </responsible_party>
  <keyword>Lucentis</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Triamcinolone Acetonide</keyword>
  <keyword>Vitrectomy</keyword>
  <keyword>PDR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

